Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Another day, another molecular glue deal in the biopharma world. This time around, it’s Eli Lilly partnering with the private startup Magnet Biomedicine on the
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
A new immunology biotech closed its Series A, and it’s backed by investors intricately familiar with the industry. Bambusa Therapeutics Sign up to read this
AnaptysBio trumpeted a Phase 2b success in rheumatoid arthritis Wednesday morning after a similar program from Eli Lilly was discontinued late last year. Anaptys’ program
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS